| Target
Information |
| Name | Dopamine D1 receptor |
| Type of target | Successful target |
| Synonyms | D(1) dopamine receptor |
| D(1A) dopamine receptor |
| Disease | Parkinson's disease [1] |
| Drug(s) | Fenoldopam |  | Approved | Hypertension | [2] |
| Methylergonovine |  | Approved | Excessive bleeding | [3] |
| Pergolide |  | Approved | Parkinson's disease | [4] |
| BSF-78438 |  | Preclinical | Schizophrenia | [5] |
| D1 agonist D2 antagonist |  | Preclinical | Schizophrenia | [5] |
| BioChemical Class | G-protein coupled receptor (rhodopsin family) |
| Pathway | Calcium signaling pathway |
| Gap junction |
| Neuroactive ligand-receptor interaction |
| UniProt ID | P21728 |
| PDB Structure | 1OZ5. |
| Function | This is one of the five types (D1 to D5) of receptors for dopamine, and the activity of this receptor is mediated by g proteins which activate adenylyl cyclase. |
| Sequence | MRTLNTSAMDGTGLVVERDFSVRILTACFLSLLILSTLLGNTLVCAAVIRFRHLRSKVTN
FFVISLAVSDLLVAVLVMPWKAVAEIAGFWPFGSFCNIWVAFDIMCSTASILNLCVISVD
RYWAISSPFRYERKMTPKAAFILISVAWTLSVLISFIPVQLSWHKAKPTSPSDGNATSLA
ETIDNCDSSLSRTYAISSSVISFYIPVAIMIVTYTRIYRIAQKQIRRIAALERAAVHAKN
CQTTTGNGKPVECSQPESSFKMSFKRETKVLKTLSVIMGVFVCCWLPFFILNCILPFCGS
GETQPFCIDSNTFDVFVWFGWANSSLNPIIYAFNADFRKAFSTLLGCYRLCPATNNAIET
VSINNNGAAMFSSHHEPRGSISKECNLVYLIPHAVGSSEDLKKEEAAGIARPLEKLSPAL
SVILDYDTDVSLEKIQPITQNGQHPT
|
| Target Validation | Click to Find Target Validation Information. |
| Inhibitor | (+)- |  | [6] |
| (+)- |  | [6] |
| (+)-BUTACLAMOL |  | [7] |
| (+/-)-nantenine |  | [8] |
| (-)- |  | [6] |
| (R)- |  | [9] |
| (R)- |  | [10] |
| (R)- |  | [11] |
| (R)- |  | [11] |
| (R)- |  | [11] |
| (R)- |  | [11] |
| (R)- |  | [11] |
| (R)-11-Amino-2-methoxyaporphine |  | [12] |
| (R)-2,11-Diaminoaporphine |  | [12] |
| (R,S)-homoaromaline hydrochloride |  | [6] |
| (S)-BULBOCAPNINE |  | [13] |
| (S)APOMORPHINE |  | [14] |
| (S,S)-oxandrine hydrochloride |  | [6] |
| 1,2,3,7,12,12a-hexahydro-1-aza-pleiaden-5-ol |  | [13] |
| 1,2,3,7,12,12a-hexahydro-1-aza-pleiadene-5,6-diol |  | [13] |
| 1,2-Bis-[R- (-)-apomorphine-2'-oxy]ethane |  | [15] |
| 1- (4- |  | [16] |
| 1-Aminomethyl-3-cyclohexyl-isochroman-5,6-diol |  | [17] |
| 1-Aminomethyl-3-phenyl-isochroman-5,6-diol |  | [18] |
| 1-Aminomethyl-isochroman-5,6-diol |  | [18] |
| 1-Aminomethyl-isochroman-5,6-diol, hydrobromide |  | [18] |
| 1-Benzyl-4- (2-ethynyl-pyrrol-1-yl)-piperidine |  | [19] |
| 1-Benzyl-4- (2-iodo-pyrrol-1-yl)-piperidine |  | [19] |
| 1-Benzyl-4- (2-oxazol-5-yl-pyrrol-1-yl)-piperidine |  | [19] |
| 1-Dibenzo[b,f]oxepin-10-yl-4-methyl-piperazine |  | [20] |
| 1-[2- (2-Benzyl-phenoxy)-ethyl]-piperidine |  | [21] |
| 1-[2- (2-Benzyl-phenoxy)-ethyl]-pyrrolidine |  | [21] |
| 1-[3- (2-Benzyl-phenoxy)-propyl]-pyrrolidine |  | [21] |
| 11-Butyryloxy-N-n-propylnoraporphine |  | [22] |
| 11-Heptanoyloxy-N-n-propylnoraporphine |  | [22] |
| 11-Hexanoyloxy-N-n-propylnoraporphine |  | [22] |
| 11-Propionyloxy-N-n-propylnoraporphine |  | [22] |
| 11-valeryloxynoraporphine |  | [22] |
| 2-Methyl-8-phenyl-1,2,3,4-tetrahydro-isoquinoline |  | [23] |
| 2-methoxyapomorphine |  | [15] |
| 2-{[R- (-)-Apomorphine-2'-oxy]ethoxy}-ethanol |  | [15] |
| 3,8-dibromoboldine |  | [24] |
| 3- (1-Propyl-piperidin-3-yl)-phenol |  | [25] |
| 3-Chloroboldine |  | [24] |
| 3-Iodoboldine |  | [24] |
| 3-bromoboldine |  | [24] |
| 4- (4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one |  | [26] |
| 4-[2- (2-Benzyl-phenoxy)-ethyl]-morpholine |  | [21] |
| 5- (2-Amino-ethyl)-2-chloro-phenol, hydrobromide |  | [27] |
| 6- (2-Amino-ethyl)-biphenyl-2,3,4'-triol |  | [28] |
| 6- (2-Amino-ethyl)-biphenyl-2,3-diol |  | [28] |
| 6- (2-Dipropylamino-ethyl)-biphenyl-2,3,4'-triol |  | [28] |
| 6- (2-Dipropylamino-ethyl)-biphenyl-2,3-diol |  | [28] |
| 9-Aminomethyl-9H-fluorene-2,5,6-triol |  | [28] |
| 9-Aminomethyl-9H-fluorene-3,4-diol |  | [28] |
| A-70108 |  | [18] |
| BOLDINE |  | [24] |
| BP-897 |  | [29] |
| DIHYDREXIDINE |  | [30] |
| Ecopipam |  | [31] |
| Etoloxamine |  | [21] |
| FALCARINDIOL |  | [32] |
| FLUMEZAPINE |  | [33] |
| FLUTROLINE |  | [34] |
| GLAUCINE |  | [13] |
| IBZM |  | [35] |
| ISOCLOZAPINE |  | [36] |
| ISOLOXAPINE |  | [37] |
| L-745870 |  | [38] |
| LE 300 |  | [39] |
| MCL-516 |  | [40] |
| MELOSMINE |  | [13] |
| N- (4-Dipropylaminobutyl)-4-biphenylcarboxamide |  | [41] |
| N- (4-Propylaminobutyl)-4-biphenylcarboxamide |  | [41] |
| NORSTEPHALAGINE |  | [13] |
| PREDICENTRINE |  | [13] |
| PUKATEINE |  | [13] |
| Phenyltoloxamine |  | [21] |
| QUINPIROLE |  | [42] |
| R-N-PROPYLNORAPOMORPHINE |  | [11] |
| Ro-21-7767 |  | [43] |
| SB-271046 |  | [44] |
| SCH-12679 |  | [45] |
| SCH-24518 |  | [46] |
| SK&F-38393, SK&F-383933, SK-38393, SK-383933 |  | [18] |
| SK&F-89626, SK-89626 |  | [47] |
| STEPHOLIDINE |  | [30] |
| TEPA (possesses cytotoxic activity) |  | [48] |
| [R- (-)-Apomorphine-2-yl]- |  | [15] |
| dihydrexidine |  | [49] |
| Agonist | D1 agonist D2 antagonist |  | [5] |
| Fenoldopam |  | [2] |
| Pergolide |  | [4] |
| SKF 38393 |  | [50][51] |
| Antagonist | Methylergonovine |  | [3] |
| SCH-23390 |  | [52] |
| Binder | BSF-78438 |  | [5] |
| Multitarget | D1 agonist D2 antagonist |  | [5] |
| Pergolide |  | [4] |
| Cross References |
3D Structure
Related Literature
On-Line
Medical Dictionary |
| Ref 1 | Locomotor behavior of dopamine D1 receptor transgenic/D2 receptor deficient hybrid mice. Brain Res. 2001 Jun 29;905(1-2):142-51. To Reference |
| Ref 2 | Etiology of iodinated radiocontrast nephrotoxicity and its attenuation by beraprost. Yakugaku Zasshi. 2008 Jul;128(7):1023-9. To Reference |
| Ref 3 | Reinforcement in an in vitro analog of appetitive classical conditioning of feeding behavior in Aplysia: blockade by a dopamine antagonist. Learn Mem. 2005 May-Jun;12(3):216-20. To Reference |
| Ref 4 | Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory. Neuropsychologia. 2009 Apr;47(5):1374-81. Epub 2009 Feb 7. To Reference |
| Ref 5 | The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. Epub 2007 Jul 31. To Reference |
| Ref 6 | J. Nat. Prod. 55(9):1281-1286 (1992) To Reference |
| Ref 7 | J Med Chem. 2000 May 18;43(10):2079-81.7-Methyl-6,7,8,9,14,15-hexahydro-5H-benz[d]indolo[2,3-g]azecine: a new heterocyclic system and a new lead compound for dopamine receptor antagonists. To Reference |
| Ref 8 | Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31. Epub 2009 Nov 20.Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. To Reference |
| Ref 9 | J Nat Prod. 1998 Jun 26;61(6):709-12.Synthesis and dopamine receptor selectivity of the benzyltetrahydroisoquinoline, (R)-(+)-nor-roefractine. To Reference |
| Ref 10 | Bioorg Med Chem Lett. 2007 Aug 1;17(15):4128-30. Epub 2007 May 23.R-(-)-N-alkyl-11-hydroxy-10-hydroxymethyl- and 10-methyl-aporphines as 5-HT1A receptor ligands. To Reference |
| Ref 11 | J Med Chem. 2008 Feb 28;51(4):983-7. Epub 2008 Feb 6.Synthesis and dopamine receptor affinities of N-alkyl-11-hydroxy-2-methoxynoraporphines: N-alkyl substituents determine D1 versus D2 receptor selectivity. To Reference |
| Ref 12 | Bioorg Med Chem. 2008 Jul 15;16(14):6675-81. Epub 2008 Jun 5.Synthesis and pharmacological investigation of novel 2-aminothiazole-privileged aporphines. To Reference |
| Ref 13 | J Med Chem. 2007 Jan 25;50(2):171-81.Advances in development of dopaminergic aporphinoids. To Reference |
| Ref 14 | J Med Chem. 1990 Jun;33(6):1800-5.Synthesis and dopamine receptor affinities of enantiomers of 2-substituted apomorphines and their N-n-propyl analogues. To Reference |
| Ref 15 | Bioorg Med Chem. 2008 Apr 15;16(8):4563-8. Epub 2008 Feb 15.Synthesis and neuropharmacological characterization of 2-O-substituted apomorphines. To Reference |
| Ref 16 | Bioorg Med Chem Lett. 2006 Jun 1;16(11):2955-9. Epub 2006 Mar 24.Synthesis and biological investigations of dopaminergic partial agonists preferentially recognizing the D4 receptor subtype. To Reference |
| Ref 17 | J Med Chem. 1991 Oct;34(10):2946-53.Synthesis and pharmacological evaluation of 1-(aminomethyl)-3,4-dihydro-5-hydroxy-1H-2-benzopyrans as dopamine D1 selective ligands. To Reference |
| Ref 18 | J Med Chem. 1990 Nov;33(11):2948-50.(1R,3S)-1-(aminomethyl)-3,4-dihydro-5,6-dihydroxy-3-phenyl-1H-2-benzopyran: a potent and selective D1 agonist. To Reference |
| Ref 19 | Bioorg Med Chem Lett. 1999 Nov 1;9(21):3143-6.Piperidinylpyrroles: design, synthesis and binding properties of novel and selective dopamine D4 receptor ligands. To Reference |
| Ref 20 | J Med Chem. 1982 Jul;25(7):855-8.Affinity of 10-(4-methylpiperazino)dibenz[b,f]oxepins for clozapine and spiroperidol binding sites in rat brain. To Reference |
| Ref 21 | J Med Chem. 2004 Aug 12;47(17):4155-8.Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 receptor selectivity. To Reference |
| Ref 22 | Bioorg Med Chem. 2008 Sep 15;16(18):8335-8. Epub 2008 Aug 28.N-Propylnoraporphin-11-O-yl carboxylic esters as potent dopamine D(2) and serotonin 5-HT(1A) receptor dual ligands. To Reference |
| Ref 23 | J Med Chem. 1981 Sep;24(9):1107-10.Synthesis and evaluation of 1,2,3,4-tetrahydro[1]benzothieno[2,3-h]isoquinolines as dopamine antagonists. To Reference |
| Ref 24 | J Nat Prod. 2000 Apr;63(4):480-4.Halogenated boldine derivatives with enhanced monoamine receptor selectivity. To Reference |
| Ref 25 | J Med Chem. 1988 Aug;31(8):1621-5.Dopamine autoreceptor agonists as potential antipsychotics. 1. (Aminoalkoxy)anilines. To Reference |
| Ref 26 | J Med Chem. 2010 Sep 9;53(17):6386-97.Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential. To Reference |
| Ref 27 | J Med Chem. 1992 Nov 13;35(23):4408-14.Synthesis and pharmacological characterization of 2-(4-chloro-3-hydroxyphenyl)ethylamine and N,N-dialkyl derivatives as dopamine receptor ligands. To Reference |
| Ref 28 | J Med Chem. 1986 Oct;29(10):1904-12.Synthesis and dopaminergic binding of 2-aryldopamine analogues: phenethylamines, 3-benzazepines, and 9-(aminomethyl)fluorenes. To Reference |
| Ref 29 | Bioorg Med Chem Lett. 2004 Dec 6;14(23):5813-6.Design, synthesis, and evaluation of hexahydrobenz[f]isoquinolines as a novel class of dopamine 3 receptor ligands. To Reference |
| Ref 30 | Bioorg Med Chem. 2009 Oct 1;17(19):6898-907. Epub 2009 Aug 20.Dibenzazecine scaffold rebuilding--is the flexibility always essential for high dopamine receptor affinities? To Reference |
| Ref 31 | J Med Chem. 1989 Aug;32(8):1913-21.Synthesis and receptor affinities of some conformationally restricted analogues of the dopamine D1 selective ligand (5R)-8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl- 1H-3-benzazepin-7-ol. To Reference |
| Ref 32 | Bioorg Med Chem. 2008 Mar 15;16(6):3218-23. Epub 2007 Dec 31.Novel coumarin glycoside and phenethyl vanillate from Notopterygium forbesii and their binding affinities for opioid and dopamine receptors. To Reference |
| Ref 33 | J Med Chem. 1982 Oct;25(10):1133-40.Effects of conformationally restricted 4-piperazinyl-10H-thienobenzodiazepine neuroleptics on central dopaminergic and cholinergic systems. To Reference |
| Ref 34 | J Med Chem. 1980 Jun;23(6):635-43.Neuroleptic activity in 5-aryltetrahydro-gamma-carbolines. To Reference |
| Ref 35 | Bioorg Med Chem. 2007 Nov 1;15(21):6819-29. Epub 2007 Aug 19.In vitro affinities of various halogenated benzamide derivatives as potential radioligands for non-invasive quantification of D(2)-like dopamine receptors. To Reference |
| Ref 36 | J Med Chem. 1997 Dec 5;40(25):4146-53.Synthesis and pharmacological evaluation of triflate-substituted analogues of clozapine: identification of a novel atypical neuroleptic. To Reference |
| Ref 37 | J Med Chem. 1981 Sep;24(9):1021-6.Synthesis of clozapine analogues and their affinity for clozapine and spiroperidol binding sites in rat brain. To Reference |
| Ref 38 | Bioorg Med Chem. 2009 Jul 1;17(13):4448-58. Epub 2009 May 12.Design, synthesis and dopamine D4 receptor binding activities of new N-heteroaromatic 5/6-ring Mannich bases. To Reference |
| Ref 39 | Bioorg Med Chem Lett. 2007 Mar 1;17(5):1399-402. Epub 2006 Dec 3.Dopamine/serotonin receptor ligands. Part 15: Oxygenation of the benz-indolo-azecine LE 300 leads to novel subnanomolar dopamine D1/D5 antagonists. To Reference |
| Ref 40 | Bioorg Med Chem Lett. 2009 Jan 1;19(1):51-3. Epub 2008 Nov 13.Synthesis and neuropharmacological evaluation of esters of R(-)-N-alkyl-11-hydroxy-2-methoxynoraporphines. To Reference |
| Ref 41 | J Med Chem. 2008 Nov 13;51(21):6829-38. Epub 2008 Oct 4.Novel D3 selective dopaminergics incorporating enyne units as nonaromatic catechol bioisosteres: synthesis, bioactivity, and mutagenesis studies. To Reference |
| Ref 42 | J Med Chem. 2005 Sep 8;48(18):5771-9.Pharmacophore-guided drug discovery investigations leading to bioactive 5-aminotetrahydropyrazolopyridines. Implications for the binding mode of heterocyclic dopamine D3 receptor agonists. To Reference |
| Ref 43 | J Med Chem. 1995 Jan 20;38(2):318-27.Evaluation of cis- and trans-9- and 11-hydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridines as structurally rigid, selective D1 dopamine receptor ligands. To Reference |
| Ref 44 | Bioorg Med Chem Lett. 2008 Jan 15;18(2):738-43. Epub 2007 Nov 17.Discovery of 3-aryl-3-methyl-1H-quinoline-2,4-diones as a new class of selective 5-HT6 receptor antagonists. To Reference |
| Ref 45 | J Med Chem. 1998 Nov 5;41(23):4486-91.Modified ibogaine fragments: synthesis and preliminary pharmacological characterization of 3-ethyl-5-phenyl-1,2,3,4,5, 6-hexahydroazepino[4,5-b]benzothiophenes. To Reference |
| Ref 46 | J Med Chem. 1988 Oct;31(10):1941-6.Synthesis and pharmacological characterization of 1-phenyl-, 4-phenyl-, and 1-benzyl-1,2,3,4-tetrahydroisoquinolines as dopamine receptor ligands. To Reference |
| Ref 47 | J Med Chem. 1990 Jun;33(6):1756-64.trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: a highly potent selective dopamine D1 full agonist. To Reference |
| Ref 48 | J Med Chem. 1998 Oct 8;41(21):4165-70.N-(Iodopropenyl)-octahydrobenzo[f]- and -[g]quinolines: synthesis and adrenergic and dopaminergic activity studies. To Reference |
| Ref 49 | J Med Chem. 2006 Nov 16;49(23):6848-57.trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization of a new dopamine D1 receptor full agonist. To Reference |
| Ref 50 | Involvement of dopamine receptors of different types in formation of latent inhibition of passive avoidance reaction in Wistar rats. Zh Vyssh Nerv Deiat Im I P Pavlova. 2009 Mar-Apr;59(2):185-91. To Reference |
| Ref 51 | Effect of dopamine receptor agonists on sensory nerve activity: possible therapeutic targets for the treatment of asthma and COPD. Br J Pharmacol. 2002 Jun;136(4):620-8. To Reference |
| Ref 52 | Dopamine modulates effort-based decision making in rats. Behav Neurosci. 2009 Apr;123(2):242-51. To Reference |